Relationship between Urinary Podocytes and Kidney Diseases

REFERENCES

• Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases: Is the podocyte the culprit? Kidney Int. 1998;54:687–697.
   PubMed Web of Science ®Google Scholar
• Kriz W. Podocyte is the major culprit accounting for the progression of chronic renal disease. Microsc Res Tech. 2002;57:189–195.
   PubMed Web of Science ®Google Scholar
• Laurens WE, Vanrenterghem YF, Steels PS, Van Damme BJ. A new single nephron model of focal and segmental glomerulosclerosis in the Munich-Wistar rat. Kidney Int. 1994;45:143–149.
   PubMed Web of Science ®Google Scholar
• Somlo S, Mundel P. Getting a foothold in nephrotic syndrome. Nat Genet. 2000;24:333–335.
   PubMed Web of Science ®Google Scholar
• Kerjaschki D. Caught flat-footed: Podocyte damage and the molecular bases of focal glomerulosclerosis. J Clin Invest. 2001;108:1583–1587.
   PubMed Web of Science ®Google Scholar
• Wang G, Lai FM, Lai KB, . Intra-renal and urinary mRNA expression of podocyte-associated molecules for the estimation of glomerular podocyte loss. Ren Fail. 2010;32:372–379.
   PubMed Web of Science ®Google Scholar
• Drumond MC, Deen WM. Structural determinants of glomerular hydraulic permeability. Am J Physiol (Renal Fluid Electrolyte Physiol.) 1994;266:F1–F12.
   Google Scholar
• Kriz W, Elger M, Mundel P, Lemley KV. Structure-stabilizing forces in the glomerular tuft. J Am Soc Nephrol. 1995;5:1731–1739.
   PubMedGoogle Scholar
• Yamaguchi Y, Iwano M, Suzuki D, . Epithelial-mesenchymal transition as a potential explanation for podocyte depletion in diabetic nephropathy. Am J Kidney Dis. 2009;54:653–664.
   PubMed Web of Science ®Google Scholar
• Miyauchi M, Toyoda M, Kobayashi K, . Hypertrophy and loss of podocytes in diabetic nephropathy. Intern Med. 2009;48:1615–1620.
   PubMed Web of Science ®Google Scholar
• Reidy K, Susztak K. Epithelial-mesenchymal transition and podocyte loss in diabetic kidney disease. Am J Kidney Dis. 2009;54:590–593.
   PubMed Web of Science ®Google Scholar
• Kriz W. Progressive renal failure—Inability of podocytes to replicate and the consequences for development of glomerulosclerosis. Nephrol Dial Transplant. 1996;11:1738–1742.
   PubMed Web of Science ®Google Scholar
• Schiffer M, Bitzer M, Roberts IS, . Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest. 2001;108:807–816.
   PubMed Web of Science ®Google Scholar
• Kim YH, Goyal M, Kurnit D, . Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int. 2001;60:957–968.
   PubMed Web of Science ®Google Scholar
• Nielsen JS, McNagny KM. The role of podocalyxin in health and disease. J Am Soc Nephrol. 2009;20:1669–1676.
   PubMedGoogle Scholar
• Kerjaschki D, Sharkey DJ, Farquhar MG. Identification and characterization of podocalyxin – The major sialoprotein of the renal glomerular epithelial cell. J Cell Biol. 1984;98:1591–1596.
   PubMed Web of Science ®Google Scholar
• Hara M, Yanagihara T, Kihara I. Cumulative excretion of urinary podocytes reflects disease progression in IgA nephropathy and Schonlein-Henoch purpura nephritis. Clin J Am Soc Nephrol. 2007;2:231–238.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Ushiyama C, Suzuki S, . Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant. 2000;15:1379–1383.
   PubMed Web of Science ®Google Scholar
• Garovic VD, Wagner SJ, Turner ST, . Urinary podocyte excretion as a marker for preeclampsia. Am J Obstet Gynecol. 2007;196(320):e321–e327.
   Google Scholar
• Hara M, Yamamoto T, Yanagihara T, . Urinary excretion of podocalyxin indicates glomerular epithelial cell injuries in glomerulonephritis. Nephron 1995;69:397–403.
   PubMedGoogle Scholar
• Nakamura T, Kawagoe Y, Koide H. Effect of cigarette smoking on urinary podocyte excretion in early diabetic nephropathy. Diabetes Care. 2003;26:1324–1325.
   PubMedGoogle Scholar
• Nakamura T, Ushiyama C, Hirokawa K, . Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol Dial Transplant. 2002;17:798–802.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Ushiyama C, Osada S, Hara M, Shimada N, Koide H. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 2001;50:1193–1196.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Ushiyama C, Shimada N, . Effect of the antiplatelet drug dilazep dihydrochloride on urinary podocytes in patients in the early stage of diabetic nephropathy. Diabetes Care. 2000;23:1168–1171.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Ushiyama C, Suzuki S, . The urinary podocyte as a marker for the differential diagnosis of idiopathic focal glomerulosclerosis and minimal-change nephrotic syndrome. Am J Nephrol. 2000;20:175–179.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Ushiyama C, Suzuki S, . Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy. Am J Nephrol. 2000;20:373–379.
   PubMedGoogle Scholar
• Vogelmann SU, Nelson WJ, Myers BD, Lemley KV. Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol. 2003;285:F40–F48.
   PubMed Web of Science ®Google Scholar
• Achenbach J, Mengel M, Tossidou I, . Parietal epithelia cells in the urine as a marker of disease activity in glomerular diseases. Nephrol Dial Transplant. 2008;23:3138–3145.
   PubMed Web of Science ®Google Scholar
• Lemley KV, Lafayette RA, Safai M, . Podocytopenia and disease severity in IgA nephropathy. Kidney Int. 2002;61:1475–1485.
   PubMed Web of Science ®Google Scholar
• Sato Y, Wharram BL, Lee SK, . Urine podocyte mRNAs mark progression of renal disease. J Am Soc Nephrol. 2009;20:1041–1052.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Ushiyama C, Suzuki S, . Urinary podocytes for the assessment of disease activity in lupus nephritis. Am J Med Sci. 2000;320:112–116.
   PubMed Web of Science ®Google Scholar
• Sharif K, Goyal M, Kershaw D, Kunkel R, Wiggins R. Podocyte phenotypes as defined by expression and distribution of GLEPP1 in the developing glomerulus and in nephrotic glomeruli from MCD, CNSF, and FSGS. A dedifferentiation hypothesis for the nephrotic syndrome. Exp Nephrol. 1998;6:234–244.
   PubMedGoogle Scholar
• Barisoni L, Kriz W, Mundel P, D’Agati V. The dysregulated podocyte phenotype: A novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol. 1999;10:51–61.
   PubMed Web of Science ®Google Scholar
• Pagtalunan ME, Miller PL, Jumping-Eagle S, . Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest. 1997;99:342–348.
   PubMed Web of Science ®Google Scholar
• Su J, Li SJ, Chen ZH, . Evaluation of podocyte lesion in patients with diabetic nephropathy: Wilms’ tumor-1 protein used as a podocyte marker. Diabetes Res Clin Pract. 2010;87:167–175.
   PubMed Web of Science ®Google Scholar
• Hara M, Yanagihara T, Takada T, . Urinary excretion of podocytes reflects disease activity in children with glomerulonephritis. Am J Nephrol. 1998;18:35–41.
   PubMed Web of Science ®Google Scholar
• Marshall SM. The podocyte: A major player in the development of diabetic nephropathy? Horm Metab Res. 2005;37:9–16.
   PubMedGoogle Scholar
• Yu D, Petermann A, Kunter U, Rong S, Shankland SJ, Floege J. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol. 2005;16:1733–1741.
   PubMed Web of Science ®Google Scholar
• Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: Podocyte injury comes of age in diabetic nephropathy. Diabetes 2005;54:1626–1634.
   PubMed Web of Science ®Google Scholar
• Dai HY, Zheng M, Tang RN, . The effects of angiotensin receptor blocker on phenotypic alterations of podocytes in early diabetic nephropathy. Am J Med Sci. 2011;341(3):207–214.
   PubMedGoogle Scholar
• Wang G, Lai FM, Lai KB, . Urinary messenger RNA expression of podocyte-associated molecules in patients with diabetic nephropathy treated by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker. Eur J Endocrinol. 2008;158:317–322.
   PubMed Web of Science ®Google Scholar
• Buhimschi CS, Norwitz ER, Funai E, . Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am J Obstet Gynecol. 2005;192:734–741.
   PubMed Web of Science ®Google Scholar